Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NYSE:IBIO NASDAQ:IMCC NASDAQ:UBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.84+2.5%$2.74$7.96▼$24.15$14.32M0.6315,685 shs37,511 shsIBIOiBio$0.73-0.9%$0.81$0.64▼$6.89$12.11M0.941.49 million shs275,117 shsIMCCIM Cannabis$2.81-2.1%$2.85$1.29▼$7.12$11.61M2.1973,412 shs30,823 shsUBXUNITY Biotechnology$0.18-40.4%$0.56$0.20▼$3.10$3.08M0.92284,137 shs3.73 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+7.78%+12.60%+17.37%-57.52%-83.94%IBIOiBio-2.77%+1.32%-1.12%-19.52%-65.76%IMCCIM Cannabis-4.97%-14.07%+2.87%+92.62%+29.28%UBXUNITY Biotechnology0.00%0.00%-77.63%-81.68%-87.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AIBIOiBio1.2553 of 5 stars3.50.00.00.00.60.00.6IMCCIM Cannabis0.2356 of 5 stars0.02.00.00.03.30.00.0UBXUNITY Biotechnology4.1328 of 5 stars3.35.00.04.70.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AIBIOiBio 3.00Buy$5.00582.04% UpsideIMCCIM Cannabis 0.00N/AN/AN/AUBXUNITY Biotechnology 2.50Moderate Buy$3.751,994.97% UpsideCurrent Analyst Ratings BreakdownLatest UBX, IMCC, ALVR, and IBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.005/27/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUNITY BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.005/5/2025IBIOiBioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AIBIOiBio$375K32.29N/AN/A$1.41 per share0.52IMCCIM Cannabis$39.44M0.29N/AN/A$1.03 per share2.73UBXUNITY BiotechnologyN/AN/AN/AN/A$0.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)IBIOiBio-$24.91MN/A0.00N/AN/AN/A-73.15%-45.51%N/AIMCCIM Cannabis-$7.72M-$0.64N/AN/AN/A-9.10%-122.96%-11.69%8/13/2025 (Estimated)UBXUNITY Biotechnology-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%8/5/2025 (Estimated)Latest UBX, IMCC, ALVR, and IBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025UBXUNITY Biotechnology-$0.30N/AN/AN/AN/AN/A5/15/2025Q1 2025IMCCIM Cannabis-$0.2540$0.06+$0.3140$0.06$11.45 million$8.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/AUBXUNITY BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78IBIOiBio0.051.761.76IMCCIM Cannabis0.100.720.59UBXUNITY BiotechnologyN/A1.951.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%IBIOiBio7.90%IMCCIM Cannabis7.68%UBXUNITY Biotechnology29.49%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%IBIOiBio0.58%IMCCIM Cannabis5.91%UBXUNITY Biotechnology5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableIBIOiBio10016.52 million9.82 millionN/AIMCCIM Cannabis3404.04 million3.81 millionNot OptionableUBXUNITY Biotechnology6017.21 million16.21 millionOptionableUBX, IMCC, ALVR, and IBIO HeadlinesRecent News About These CompaniesUnity Stock Crashes Nearly 50% After Nasdaq Delisting NoticeJune 30, 2025 | finance.yahoo.comUnity Biotechnology stock plunges after Nasdaq delisting noticeJune 30, 2025 | za.investing.comUnity Biotechnology Inc News (UBX) - Investing.comJune 26, 2025 | investing.comUBX Unity Biotechnology, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 6, 2025 | msn.comBay Area biotech company Unity, once worth $700M, lays off entire remaining workforceMay 5, 2025 | msn.comSouth San Francisco biotech company lays off entire workforce, including CEOMay 5, 2025 | msn.comUnity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 rolesMay 5, 2025 | fiercebiotech.comFUNITY Biotechnology to Present at the ARVO 2025 Annual MeetingMay 1, 2025 | globenewswire.comNEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325April 25, 2025 | ophthalmologytimes.comOUNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business UpdatesApril 22, 2025 | globenewswire.comUnity Biotechnology price target lowered to $4 from $8 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology price target lowered to $4 from $6 at ChardanMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology announces results from ASPIRE Phase 2b study in DMEMarch 25, 2025 | markets.businessinsider.comUnity reports topline outcomes from trial of diabetic macular oedema therapyMarch 25, 2025 | msn.comUNITY Biotechnology tanks on mixed results for eye disease drugMarch 25, 2025 | thepharmaletter.comTUBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyMarch 25, 2025 | zacks.comUNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular EdemaMarch 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUBX, IMCC, ALVR, and IBIO Company DescriptionsAlloVir NASDAQ:ALVR$2.84 +0.07 (+2.53%) As of 07/24/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.iBio NYSE:IBIO$0.73 -0.01 (-0.88%) Closing price 04:00 PM EasternExtended Trading$0.73 -0.01 (-0.70%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.IM Cannabis NASDAQ:IMCC$2.81 -0.06 (-2.09%) Closing price 04:00 PM EasternExtended Trading$2.75 -0.06 (-2.14%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.UNITY Biotechnology NASDAQ:UBX$0.18 -0.12 (-40.43%) Closing price 07/8/2025Extended Trading$0.18 0.00 (0.00%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
